Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).

Jódar E, Michelsen M, Polonsky W, Réa R, Sandberg A, Vilsbøll T, Warren M, Harring S, Ziegler U, Bain S

Diabetes, obesity & metabolism27 Apr 2020Cited by 29 (Europe PMC)

PMID32227613PMCIDPMC7383680DOI10.1111/dom.14039PepBankPUB-32227613

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes at high cardiovascular risk, semaglutide improved the SF-36 physical component summary score more than placebo.
In plain wordsIn adults with type 2 diabetes at high heart risk, semaglutide improved the physical quality-of-life score more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 physical component summary (PCS) score
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 104 weeksAs given in this study (human).
Measurements
PCS change
1 points
semaglutide
PCS change
0.4 points
placebo
Unadjusted treatment effect on PCS
0.7 points
versus placebo
Source sentences
Summary
Mean change in overall PCS score was +1.0 with semaglutide versus +0.4 with placebo, and +0.5 versus -0.2 for MCS.
2 context sentences(design, population, supporting numbers)
Summary · context
The treatment effect of semaglutide versus placebo (unadjusted estimate) was 0.7 [(95% confidence interval 0.1, 1.2); P = 0.018]
Summary · context
The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis.
Report a problemFND-3222761301
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes at high cardiovascular risk, the unadjusted semaglutide effect on the SF-36 mental component summary score versus placebo was not significant.
In plain wordsIn adults with type 2 diabetes at high heart risk, semaglutide did not clearly improve the mental quality-of-life score compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeSF-36 mental component summary (MCS) score
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Mental health and mood
Studied dose
Dose not stated · 104 weeksAs given in this study (human).
Measurements
MCS change
0.5 points
semaglutide
MCS change
−0.2 points
placebo
Unadjusted treatment effect on MCS
0.7 points
versus placebo
Source sentences
Summary
Mean change in overall PCS score was +1.0 with semaglutide versus +0.4 with placebo, and +0.5 versus -0.2 for MCS.
2 context sentences(design, population, supporting numbers)
Summary · context
The unadjusted treatment effect on MCS [0.7 (-0.0, 1.5), P = .054]
Summary · context
The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis.
Report a problemFND-3222761302
03HumanRandomized controlled trialMechanism
In adults with type 2 diabetes at high cardiovascular risk, the semaglutide effect on the PCS score versus placebo was reduced when adjusted for change in HbA1c and for change in body weight.
In plain wordsIn adults with type 2 diabetes at high heart risk, part of semaglutide's effect on physical quality of life may work through HbA1c and weight.
Peptide
Semaglutide
Outcome
Not applicableMediation of the PCS effect by HbA1c and body weight
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 104 weeksAs given in this study (human).
Source sentences
Summary
this was reduced when adjusted for change in HbA1c [0.4 (-0.2, 1.0), P = .167] and body weight [0.3 (-0.3, 0.9), P = .314]
1 context sentence(design, population, supporting numbers)
Summary · context
The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis.
Report a problemFND-3222761303
04HumanRandomized controlled trialMechanism
In adults with type 2 diabetes at high cardiovascular risk, the unadjusted semaglutide effect on the MCS score was reduced only when adjusted for change in HbA1c.
In plain wordsIn adults with type 2 diabetes at high heart risk, the semaglutide effect on mental quality of life shrank only after adjusting for HbA1c change.
Peptide
Semaglutide
Outcome
Not applicableMediation of the MCS effect by HbA1c
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Mental health and mood
Studied dose
Dose not stated · 104 weeksAs given in this study (human).
Source sentences
Summary
was only reduced when adjusted for change in HbA1c [0.3 (-0.4, 1.1), P = .397]
1 context sentence(design, population, supporting numbers)
Summary · context
The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis.
Report a problemFND-3222761304
05HumanRandomized controlled trialMechanism
In adults with type 2 diabetes at high cardiovascular risk, adjusting separately for all other parameters did not qualitatively change the semaglutide effect on PCS and MCS.
In plain wordsIn adults with type 2 diabetes at high heart risk, adjusting for the other factors did not clearly change semaglutide's effect on quality-of-life scores.
Peptide
Semaglutide
Outcome
No significant changePCS and MCS effects adjusted for other parameters
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 104 weeksAs given in this study (human).
Source sentences
Summary
When adjusting for all other parameters separately, the estimated effect of semaglutide on PCS and MCS qualitatively did not change.
1 context sentence(design, population, supporting numbers)
Summary · context
The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis.
Report a problemFND-3222761305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01720446

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3,29721 Feb 2013 to 15 Mar 2016

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 27 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.